Semaglutide vs Tirzepatide

Semaglutide is a GLP-1 analogue described as acting at the GLP-1 receptor. Tirzepatide is a GIP-derived peptide described as acting at GIP and GLP-1 receptors. Tirzepatide is not GLP-2; GLP-2 names a different molecule.

Both compounds are acylated, but that shared feature does not establish the same receptor profile or exposure. The number of receptor pathways alone cannot establish potency, efficacy or equivalence between experimental materials.

A direct clinical comparison exists: SURPASS-2 was an open-label phase 3 trial in people with type 2 diabetes, lasting 40 weeks. Its primary endpoint was change in HbA1c. That comparison concerns its preparations, population and design, not these catalog vials or every possible setting.

Semaglutide: Semaglutide is a glucagon-like peptide-1 analog with substitutions at positions 8 and 34 and a fatty acid chain attached through a spacer. In preclinical models, it binds to the GLP-1 receptor and acts as an agonist of that pathway. It has been investigated in models of glucose homeostasis and metabolic regulation in animal studies.

Tirzepatide: Tirzepatide is a synthetic 39-amino-acid peptide derived from the GIP sequence, with acylation at a lysine residue. In research literature, it binds to GIP and GLP-1 receptors and acts as a dual agonist of both pathways. It has been studied in models of incretin signaling and metabolic regulation in preclinical research.

Semaglutide: Replacing alanine with Aib at position 8 reduces degradation by dipeptidyl peptidase 4 in in vitro studies. Acylation promotes albumin binding and modifies the kinetics of receptor exposure in experimental models.

Tirzepatide: The molecule has differential affinity for GIPR and GLP-1R, both of which are Gs protein-coupled receptors. Activation of these receptors modulates cyclic AMP production in cellular models.

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.